Re-watch sessions on-demand:
Click Here to View! Contact anyone at the conference
Delivered Digitally on 25 - 26 May 2021
Anglonordic was delivered digitally this year and is ordinarily exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other.
With an established format of panel discussions, parallel technology and biotech investment digital rooms, plus 1:1 video meetings, this conference provides exceptional value.
Investors with funds attend free-of-charge.
The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors.
This year the Conference Supported Charity was Brain Tumour Research.
What our delegates say...
“Anglonordic is a great event to meet quality investors and companies - it is very well run and also includes panels covering interesting topics” Tim Luker, VP Emerging Technology & Innovation, Eli Lilly.
"This was a great meeting, content quality and organisation."
"Some very good panels and topics, good quality investors and companies"
"The conference is a fantastic event to meet new contacts, given the invitation only status it is well attended with quality investors and companies"
3B Future Health Fund (formerly Helsinn Investment Fund), 4BIO Capital, Advent Life Sciences, Albion Technology & General VCT plc, Alpha Blue Ocean, Alpha Bronze Life Sciences Opportunity Fund, Apollo Ventures, Aratus Capital, Arix Bioscience, Arvic AG, Axilium Holding AB, Axon Capital Partners, BioLucidity Advisors, Bioscience Managers, Biotechnology Business Institute, Bond Asian Ventures Limited, Cascara Ventures Bvba, Catapult Ventures, China Life Franklin Asset Management, Curam Capital Management, DeBere Capital Partners, Deep Science Ventures, Draper Esprit, Eir Ventures, Emerson Collective, ESM Biotech, Esperante, European Investment Bank, GIMV, GL Capital, GreenSky Capital, Hermes Partners Intl Ltd., i2020 Accelerator, Ignite Capital Partners, Inc., Inkef Capital BV, Innovate UK, Inveready Asset Management, IP Group, IPF Partners, Julz Co LLC, Kreos Capital, Kurma Partners SA, Limerston Capital Partners, Longacre Funding Partners Plc, Luminous Ventures, Lundbeckfonden Ventures, M Ventures, Mercia Asset Management, Momentum Biotech, MVM Partners, National Institute for Health Research, NeoMed, New Grounds Venture Capital, Newables and Syndicate Room, Norgine Ventures, Novalis Biotech Acceleration, Novo Holdings, NRW.BANK, o2h Ventures, Optum Ventures, Oxford Technology 3 VCT, Panakes Partners SGRSpa, Pontifax, Questra Limited, RBV Capital, R-Pharm, Rosetta Capital Ltd, Ruffena Capital Ltd, Seroba Life Sciences, Seventure Partners, SHS, SR One, SV Health Investors, Swelife International, Syncona, TRILANTIC EUROPE, UCB Ventures, UK Innovation & Science Seed Fund, V-Bio Ventures, Vickers Venture Partners, Xeraya Capital, and XOventure GmbH.